Lopchuk Lab retweeted
‘We spent a long time trying to develop sulfur(VI) versions of the transfer reagents but could never engineer a system with the balance of stability & reactivity that was needed to enable the late-functionalisation process,’ says researcher Justin Lopchuk
chemistryworld.com/news/cova…
Lopchuk Lab retweeted
Enjoyed spending time with @MoffittNews Drug Discovery team during our latest listening tour.
It’s exciting to hear about the work underway to identify new cancer targets, develop promising small molecule therapies and move discoveries from the lab toward the clinic.
@StuartMaudsley @monastyrskyi @LopchukLab @karenluMD #CancerResearch #CancerTherapeutics #TranslationalResearch
Lopchuk Lab retweeted
Preparation of Enantiopure Bifunctional S(VI) Transfer Reagent (t-BuSF)
Submitting Authors: Zachary Shultz, Eve Hall, Prakash Warghude, Yun-Pu Chang, Justin M. Lopchuk
Checking Authors: Taylor A. Stephens and Tehshik P. Yoon
Lopchuk Lab retweeted
Today we’re celebrating the launch of @AccelerOnc, the first U.S. venture studio focused solely on oncology innovation and founded by Moffitt. By merging data, expertise and urgency, we’re driving bold ideas forward to prevent and cure cancer.
#InnovationToImpact
Lopchuk Lab retweeted
Advance your career in #CancerResearch with the Moffitt Cancer PhD program! Application deadline: December 1, 2025
Are you passionate about fighting cancer? Our program prepares future scientists with a rigorous curriculum and offers four unique majors:
• Cancer Biology
• Cancer Chemical Biology
• Cancer Immunology & Immunotherapy
• Integrated Mathematical Oncology
Why Moffitt?
• Access to top research facilities
• Collaborate with world-leading scientists
• Hands-on experience in cutting-edge research
• Supportive environment for innovation
• Unmatched translational environment, turning discoveries into cures
Start your journey to make a difference in cancer care and innovation.
Learn more and apply now: bit.ly/3YH7yfH
Lopchuk Lab retweeted
🧪NEWS from @LopchukLab
Moffitt Researchers Develop New Chemical Method to Enhance Drug Discovery
moffitt.org/newsroom/news-re…
Today in @NatureComms we report the rapid, stereocontrolled synthesis of sulfinamides, sulfonamidamides, and sulfoximines by leveraging a mild strain-release driven amine exchange with t-BuSF, our lab's recently reported S(VI) reagent. rdcu.be/dQXqz
Lopchuk Lab retweeted
Congrats to @LopchukLab and colleagues for their innovative scalable synthesis of withanolides, compounds in plants that inhibit #cancer cell growth. Their groundbreaking work was recently published in @ScienceAdvances. moffitt.org/newsroom/news-re…
Lopchuk Lab retweeted
A new Moffitt publication from @LopchukLab shares an organic synthesis breakthrough: cobalt-catalyzed regioselective hydroamination of unactivated olefins using diazirines.
This versatile method produces diaziridines easily converted to primary amines, hydrazines and heterocycles. It has significant implications for medicinal chemistry and cancer drug development.
👉 Read here: nature.com/articles/s41467-0…
Lopchuk Lab retweeted
Online now: Direct catalytic photodecarboxylative amination of carboxylic acids with diazirines for divergent access to nitrogen-containing compounds dlvr.it/T9WR53
Lopchuk Lab retweeted
Congrats to @LopchukLab and colleagues on their publication in @NatureChemistry on the development of a new reagent that allows a more efficient approach to make sulfoximines, sulfonimidoyl fluorides and sulfonimidamides that may be used in medicines.
moffitt.org/newsroom/news-re…
Lopchuk Lab retweeted
New reagent improves process of making sulfur-containing compounds that may be used in medicines doi.org/gtfj2h phys.org/news/2024-01-reagen…
Lopchuk Lab retweeted
This year, move your career forward by applying to the Innovators of Tomorrow Symposium! This competitive program is a great opportunity to visit our campus in Tampa to present your research and learn about postdoc training and support at Moffitt! Moffitt.org/MIOT
Lopchuk Lab retweeted
Y'all know #FloHet2024 is a grass roots effort, right?! Please help spread the word: RT, share with colleagues (Jr. Profs, graduate students, PDs!), and w/ anyone else whom would benefit form participating! Also, industry folks, PLEASE sponsor! 🙏 I'll do all the legwork! :)
Submit your #FloHet2024 Lecture/Poster Abstract now! Review begins 09/01. Help us create a conference w/ diverse #OChem research & researchers by submitting your abstract ASAP! #READMYLIPS: The conference will be #SCHOLARLY, #AFFORDABLE, & #FUN. more here: flohet.com/
Lopchuk Lab retweeted
Students and postdocs - we have several registration fee waivers for WIPOS 2022. These will be awarded on a first-come-first-served basis, and priority will be given to minority and female applicants. Please contact @kurtilaszlo [email protected] if you are interested in signing up.
Lopchuk Lab retweeted
Follow up to my February virtual meeting with the #DrugDiscovery team @MoffittNews! Making up for lost time with an in-person lab tour. So impressed with the large number of trainees in #DrugDiscovery and chemistry! @MoffittResearch @monastyrskyi @LopchukLab @LabElsaFlores
Lopchuk Lab retweeted
Please join us for the 28th Congress of the International Society of Heterocyclic Chemistry (ISHC) in sunny Santa Barbara from 28 August to 2 September! We’ve got a great lineup of speakers and a beautiful location at UCSB: ishc.chem.uci.edu
Lopchuk Lab retweeted
New insights - Ceralasertib inhibits TAF1 and stabilizes a closed structural state of the TAF1 tandem bromodomain:
go.acs.org/vi
Lopchuk Lab retweeted
Feb issue live! Featuring...
@GianettiGroup 💡catalytic α-arylation of cyclic ketones
@LopchukLab stereospecific α-(hetero)arylation of sulfoximines & sulfonimidamides
@K_KalantarZadeh @nicgaston forming patterns during solidification of liquid metals
go.nature.com/3rFp2IS
Lopchuk Lab retweeted
Moffitt SPARK is now accepting applications. The 10-week summer program is for college undergraduate students who are interested in pursuing careers in biomedical and related sciences. Deadline to apply is 2/15. Learn more here: bit.ly/3yz7qQO





























